PODD gains momentum as Omnipod 5 adoption accelerates, margins scale, and earnings estimates rise despite macro and concentration risks.

Insulet Corporation (NASDAQ:PODD) is one of the best growth stocks to buy in 2026. On December 18, Truist lowered the firm’s ...

Baystreet.ca News Commentary – Pharmaceutical markets are witnessing drug delivery devices surge toward $862.16 billion by ...

Many investors pay attention to mid-cap stocks because they have established business models and expansive market ...

Fintel reports that on December 18, 2025, Truist Securities maintained coverage of Insulet (NasdaqGS:PODD) with a Buy recommendation. Analyst Price Forecast Suggests 31.68% Upside As of December 5, ...

Fintel reports that on December 16, 2025, Evercore ISI Group initiated coverage of Insulet (NasdaqGS:PODD) with a Outperform recommendation. Analyst Price Forecast Suggests 33.61% Upside As of ...

In a report released on December 16, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Insulet, with a price target of $380.00. The company’s shares closed yesterday at $288.73.

Insulet Corporation (NASDAQ:PODD) develops, manufactures, and sells insulin delivery systems for people with ...

Despite record beef prices linked to a country-wide cattle shortage, long lines formed at butcher shops Tuesday. TMJ4 spoke with some in line to hear how the price hike is affecting their wallets.